Applied Molecular Transport Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $26.48 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Applied Molecular Transport Inc had its IPO on 2020-06-05 under the ticker symbol AMTI.
The company operates in the Healthcare sector and Biotechnology industry. Applied Molecular Transport Inc has a staff strength of 125 employees.
Shares of Applied Molecular Transport Inc opened at $0.34 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $0.31 - $0.38, and closed at $0.32.
This is a -4.48% slip from the previous day's closing price.
A total volume of 255,340 shares were traded at the close of the day’s session.
In the last one week, shares of Applied Molecular Transport Inc have slipped by -18.58%.
Applied Molecular Transport Inc's Key Ratios
Applied Molecular Transport Inc has a market cap of $26.48 million, indicating a price to book ratio of 0.5961 and a price to sales ratio of 0.
In the last 12-months Applied Molecular Transport Inc’s revenue was $0 with a gross profit of $-30105000 and an EBITDA of $-127499000. The EBITDA ratio measures Applied Molecular Transport Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Applied Molecular Transport Inc’s operating margin was 0% while its return on assets stood at -49.3% with a return of equity of -100.73%.
In Q3, Applied Molecular Transport Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Applied Molecular Transport Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Applied Molecular Transport Inc’s profitability.
Applied Molecular Transport Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0552. Its price to sales ratio in the trailing 12-months stood at 0.
Applied Molecular Transport Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $124.61 million
- Total Liabilities
- $14.12 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Applied Molecular Transport Inc ended 2023 with $124.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $124.61 million while shareholder equity stood at $78.40 million.
Applied Molecular Transport Inc ended 2023 with $0 in deferred long-term liabilities, $14.12 million in other current liabilities, 4000.00 in common stock, $-343371000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $76.02 million and cash and short-term investments were $76.02 million. The company’s total short-term debt was $4,707,000 while long-term debt stood at $0.
Applied Molecular Transport Inc’s total current assets stands at $80.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.37 million and inventory worth $0.
In 2023, Applied Molecular Transport Inc's operating cash flow was $-223000.00 while its capital expenditure stood at $223000.
Comparatively, Applied Molecular Transport Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Applied Molecular Transport Inc stock is currently trading at $0.32 per share. It touched a 52-week high of $8.02 and a 52-week low of $8.02. Analysts tracking the stock have a 12-month average target price of $1.48.
Its 50-day moving average was $0.52 and 200-day moving average was $1.22 The short ratio stood at 1.59 indicating a short percent outstanding of 0%.
Around 2288.6% of the company’s stock are held by insiders while 4814.3% are held by institutions.
Frequently Asked Questions About Applied Molecular Transport Inc
Similar Industry Stocks (Biotechnology)
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.